Literature DB >> 10579985

The relationship between infliximab treatment and lymphoma in Crohn's disease.

S J Bickston1, G R Lichtenstein, K O Arseneau, R B Cohen, F Cominelli.   

Abstract

The relationship between chronic inflammatory conditions and malignancy is complex. We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab. The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab. The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab. The lymphoma presented with pleural effusions, mediastinal and cervical adenopathy, and no gastrointestinal lesion. We describe the implications of these cases for the use of immunomodulatory therapy in CD and the questionable association between CD and lymphoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579985     DOI: 10.1016/s0016-5085(99)70294-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

1.  Immunoactive cannabinoids: therapeutic prospects for marijuana constituents.

Authors:  S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Management of difficult inflammatory bowel disease: where are we now?

Authors:  DS Rampton
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

Review 3.  Clinically useful monoclonal antibodies in treatment.

Authors:  E Drewe; R J Powell
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

Review 4.  Infliximab treatment for Crohn's disease.

Authors:  C A Conroy; R Cattell
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

5.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.

Authors:  R J Farrell; Y Ang; P Kileen; D S O'Briain; D Kelleher; P W Keeling; D G Weir
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 6.  Biologics in inflammatory disease: infliximab associated risk of lymphoma development.

Authors:  C Bucher; L Degen; S Dirnhofer; M Pless; R Herrmann; P Schraml; P Went
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 7.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 8.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

9.  Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors:  Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

10.  Colorectal cancer risk in Crohn's disease.

Authors:  Hugh-James Freeman
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.